Immunic Return On Capital Employed from 2010 to 2025

IMUX Stock  USD 1.18  0.01  0.85%   
Immunic Return On Capital Employed yearly trend continues to be fairly stable with very little volatility. Return On Capital Employed is likely to outpace its year average in 2025. During the period from 2010 to 2025, Immunic Return On Capital Employed regression line of annual values had r-squared of  0.33 and arithmetic mean of  70.19. View All Fundamentals
 
Return On Capital Employed  
First Reported
2010-12-31
Previous Quarter
(3.86)
Current Value
(3.67)
Quarterly Volatility
195.91743661
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 94.9 K, Interest Expense of 730.2 K or Other Operating Expenses of 119.8 M, as well as many indicators such as Price To Sales Ratio of 17.3 K, Dividend Yield of 0.0064 or PTB Ratio of 1.46. Immunic financial statements analysis is a perfect complement when working with Immunic Valuation or Volatility modules.
  
Check out the analysis of Immunic Correlation against competitors.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Latest Immunic's Return On Capital Employed Growth Pattern

Below is the plot of the Return On Capital Employed of Immunic over the last few years. It is Immunic's Return On Capital Employed historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunic's overall financial position and show how it may be relating to other accounts over time.
Return On Capital Employed10 Years Trend
Slightly volatile
   Return On Capital Employed   
       Timeline  

Immunic Return On Capital Employed Regression Statistics

Arithmetic Mean70.19
Geometric Mean2.32
Coefficient Of Variation279.13
Mean Deviation125.47
Median(0.70)
Standard Deviation195.92
Sample Variance38,384
Range576
R-Value(0.58)
Mean Square Error27,412
R-Squared0.33
Significance0.02
Slope(23.76)
Total Sum of Squares575,755

Immunic Return On Capital Employed History

2025 -3.67
2024 -3.86
2023 -3.36
2022 -1.04
2021 -0.72
2020 -0.31

About Immunic Financial Statements

Immunic investors use historical fundamental indicators, such as Immunic's Return On Capital Employed, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Capital Employed(3.86)(3.67)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.